Drug Approval | October 21, 2024
Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
KIMS already have a multi-specialty hospital and gastro unit at Vizag
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Subscribe To Our Newsletter & Stay Updated
